Scott Armstrong, MD, PhD
Director of Translational Research in Pediatric Cancer and Blood Diseases, Children’s Hospital Boston and Dana-Farber Cancer Institute.
Attending Physician, Department of Pediatric Oncology, Children’s Hospital Boston and Dana-Farber Cancer Institute.
Associate Professor of Pediatrics, Harvard Medical School.
Pediatric oncologist Scott Armstrong, MD, PhD, is a leader in leukemia research whose focus on the disease genes has led to several landmark findings and points to promising new therapies. As the recently appointed Director of Translational Research in Pediatric Cancer and Blood Diseases at Children’s Hospital Boston and Dana-Farber Cancer Institute, Dr. Armstrong facilitates studies that can speed therapeutic discoveries to the patients who need them.
Among Dr. Armstrong’s most notable achievements was discovery of mixed lineage leukemia (MLL), a rare, lethal blood cancer that strikes infants in their first year and is genetically distinct from other acute lymphoblastic leukemias (ALL). This work led to the development of new therapies that are now being tested in patients. In related research, Dr. Armstrong recently identified changes in chromosome structure as a critical initial step in leukemia development which has prompted a search for therapies that can reverse this process and eradicate leukemia cells.
Dr. Armstrong received his MD and PhD from the University of Texas Southwestern Medical School. He completed his residency at Children’s Hospital Boston and fellowship at both Children’s and Dana-Farber. He has published in top journals, including Nature, Science, Nature Genetics, and Cancer Cell, and received Scholar Awards from the American Society of Hematology and the Leukemia and Lymphoma Society. He received the Wilson S. Stone Memorial Award from the M.D. Anderson Cancer Center in 2006, which recognizes a young researcher who has made outstanding contributions to biomedical sciences in the United States. This year he received the McCulloch and Till Award from the International Society of Experimental Hematology, which recognizes emerging international leaders in stem cell biology.
Back to Top |
